Acute Gout Clinical Trial
Official title:
The Phase Ib/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Genakumab for Injection in Patients With Acute Gout
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout
Phase Ib: single arm, open lable, single dose, dose escalation,design. There are 3 dose groups with 10 participant s in each group. Phase II: randomized, double-blind, active control design.There are 2 dose groups of Genakumab for Injection with 30 participant s in each group and 1 group of Compound Betamethasone Injection with 30 praticipants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02674776 -
Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
|
Phase 3 | |
| Not yet recruiting |
NCT05925166 -
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
|
N/A | |
| Completed |
NCT00798369 -
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
|
Phase 2 | |
| Completed |
NCT01080131 -
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
|
Phase 3 | |
| Recruiting |
NCT05936268 -
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
|
Phase 2 | |
| Not yet recruiting |
NCT05936281 -
Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy
|
Phase 2 | |
| Recruiting |
NCT05588908 -
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05698680 -
Prednisolone Versus Colchicine for Acute Gout in Primary Care
|
Phase 4 | |
| Recruiting |
NCT05983445 -
Safety & Efficacy of Genakumab in Patients With Frequent Flares
|
Phase 3 | |
| Completed |
NCT00142558 -
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
|
Phase 4 | |
| Not yet recruiting |
NCT06169891 -
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
|
Phase 3 | |
| Completed |
NCT01029652 -
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
|
Phase 3 | |
| Withdrawn |
NCT00997581 -
Apremilast Therapy for Acute Gouty Arthritis
|
Phase 2 |